Replimune Group, Inc.
REPL
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.3B
$15.04
▼ -1.64%
P/E
-4.77
Mkt Cap
$1.3B
52-Wk Range
$1.50–$16.33
52-Week Range
$1.50 - $16.33
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 149.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary oncolytic immuno-gene therapy platform with multi-mechanism approach
- First-in-class potential with selectively replicating HSV-1 combined with immune activation
- Differentiated pipeline addressing multiple immune checkpoints and T-cell stimulation simultaneously
- Clinical validation across multiple solid tumor indications and cutaneous malignancies
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Phase II advancement of RP1 in cutaneous squamous cell carcinoma with potential for accelerated approval pathways
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+67.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying REPL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 14, 2026
Reported EPS of -$0.72 vs -$0.69 consensus (-3.8% surprise).
EPS surprise · last 4Q
0 of 2 beats
Estimate
Actual
Q3 26
-3.8%
Q2 26
-14.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q4 26
Q1 27
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
9 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
44%
Sell
22%
Median Price Target
—
Latest: BMO Capital · Aug 7, 2026
vs Industry
How REPL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related